No material corporate news briefings were provided for Amgen Inc. in the 30 days preceding this report's generation date of 2026-06-01. The report is principally driven by notable institutional position changes recorded in recent 13F filings, supplemented by the most recent quarterly financial data and insider transactions [Brief - 2026-05-24].
Amgen reported trailing twelve-month revenue of $37.22 billion as of 2026-03-31, reflecting year-over-year growth of 5.76%. Net income for the same period stood at $7.80 billion, with a net margin of 20.96% and an operating margin of 28.39%. Gross margin was recorded at 48.58%. EPS growth on a year-over-year basis was 4.38%. The company held $12.04 billion in cash against total debt of $59.32 billion. The trailing P/E ratio was 23.44, with a market capitalisation of approximately $181.77 billion [SEC 10-Q - AMGN - 2026-03-31].
Insider activity over the past 30 days encompassed 68 transactions, with net direction characterised as selling and a net disposal value of approximately $400,451 [SEC Form 4 - AMGN - 2026-06]. Among institutional holders, Bridgewater expanded its reported position by 389% and Millennium added 47% to its position. Citadel reduced its position by 9.4% and AQR Capital reduced its position by 30% [SEC 13F - Bridgewater - Q1 2026] [SEC 13F - Millennium - Q1 2026] [SEC 13F - Citadel - Q1 2026] [SEC 13F - AQR Capital - Q1 2026].
The 10-year US Treasury yield stood at 4.45% and the 2-year yield at 3.99% as of the report date, reflecting a normal yield curve with a spread of 46 basis points between the two tenors [FRED DGS10] [FRED DGS2]. These rate conditions represent the broad fixed-income environment in which large-cap pharmaceutical equities such as AMGN are currently traded.
This report was triggered by material institutional position changes identified in the most recent round of 13F filings, particularly the divergent activity across multiple major quantitative and macro-oriented fund managers noted above.